Patients with recurrent platinum-sensitive EOC with no more than @ prior courses of chemotherapy were randomized to single-agent sorafenib @ mg twice daily or combination sorafenib @ mg bid ( days @-@ ) with IV carboplatin ( AUC @ ) and IV paclitaxel @ mg/m ( @ ) ( S+C / T ) every @ weeks .